Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart Failure Reviews
Erschienen in: Heart Failure Reviews 5/2022

01.09.2021

Clinical management of amyloid cardiomyopathy

verfasst von: Morris M. Kim, Clinton M. Kolseth, Dayna Carlson, Ahmad Masri

Erschienen in: Heart Failure Reviews | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical management of amyloid cardiomyopathy. In this review, we review the role of routine medical therapy in amyloid cardiomyopathy, from heart failure management to orthostatic hypotension, atrial arrhythmias, thromboembolic complications, and prevention of sudden death. We conclude by discussing approaches to patients with end-stage disease.
Literatur
1.
Abraham B et al (2020) Meta-analysis comparing torsemide versus furosemide in patients with heart failure. Am J Cardiol 125(1):92–99PubMedCrossRef
2.
Miles JA et al (2019) Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. J Cardiovasc Med (Hagerstown) 20(6):379–388CrossRef
3.
Hunt SA et al (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):e391-479PubMed
4.
Abraham WT et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377(9766):658–666PubMedCrossRef
5.
Young JB et al (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110(17):2618–2626PubMedCrossRef
6.
Yusuf S et al (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293–302PubMedCrossRef
7.
Levine TB, Olivari MT, Cohn JN (1984) Hemodynamic and regional blood flow response to captopril in congestive heart failure. Am J Med 76(5b):38–42PubMedCrossRef
8.
Kramer BL, Massie BM, Topic N (1983) Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 67(4):807–816PubMedCrossRef
9.
Bengur AR et al (1991) Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 83(2):523–527PubMedCrossRef
10.
Boldrini M et al (2013) Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 18(4):327–335PubMedPubMedCentralCrossRef
11.
12.
Pollak A, Falk RH (1993) Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 104(2):618–620PubMedCrossRef
13.
Gertz MA et al (1985) Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 55(13 Pt 1):1645PubMedCrossRef
14.
Gertz MA et al (1985) Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 55(13 Pt 1):1646PubMedCrossRef
15.
Rubinow A, Skinner M, Cohen AS (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63(6):1285–1288PubMedCrossRef
16.
17.
18.
Loavenbruck AJ et al (2016) Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? Ann Neurol 80(3):401–411PubMedPubMedCentralCrossRef
19.
Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112(13):2047–2060PubMedCrossRef
20.
Denq JC et al (1997) Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension. Clin Auton Res 7(6):321–326PubMedCrossRef
21.
Newton JL, Frith J (2018) The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. Neurology 91(7):e652–e656PubMedPubMedCentralCrossRef
22.
23.
Ho AH et al (2020) Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report. J Med Case Rep 14(1):73PubMedPubMedCentralCrossRef
24.
Grijalva CG et al (2017) Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. J Am Heart Assoc 6(10)
25.
Falk RH, Rubinow A, Cohen AS (1984) Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 3(1):107–113PubMedCrossRef
26.
Dubrey SW et al (1997) Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78(1):74–82PubMedPubMedCentralCrossRef
27.
Mints YY et al (2018) Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail 5(5):772–779PubMedPubMedCentralCrossRef
28.
29.
Feng D et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490–2497PubMedCrossRef
30.
Donnellan E et al (2020) Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol 6(9):1118–1127PubMedCrossRef
31.
Mitrani LR et al (2019) Abstract 14004: atrial fibrillation in transthyretin amyloid cardiomyopathy may present with controlled ventricular response: a retrospective study. Circulation 140(1):A14004–A14004
32.
Sanchis K et al (2019) Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid 26(3):128–138PubMedCrossRef
33.
34.
Barbhaiya CR et al (2016) Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm 13(2):383–390PubMedCrossRef
35.
Black-Maier E et al (2020) Catheter ablation of atrial fibrillation in cardiac amyloidosis. Pacing Clin Electrophysiol 43(9):913–921PubMedCrossRef
36.
Donnellan E et al (2020) Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace 22(2):259–264PubMedCrossRef
37.
Brignole M et al (2018) A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 39(45):3999–4008PubMedCrossRef
38.
Kay GN et al (1998) The ablate and pace trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators J Interv Card Electrophysiol 2(2):121–135PubMedCrossRef
39.
Donnellan E et al (2019) No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol 5(12):1473–1474PubMedCrossRef
40.
Feng D et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420–2426PubMedCrossRef
41.
Mitrani LR et al (2021) Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding. Amyloid 28(1):30–34PubMedCrossRef
42.
Dubrey S et al (1995) Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 74(5):541–544PubMedPubMedCentralCrossRef
43.
Di Bella G et al (2016) Left atrial function in cardiac amyloidosis. J Cardiovasc Med (Hagerstown) 17(2):113–121CrossRef
44.
Modesto KM et al (2005) Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J 26(2):173–179PubMedCrossRef
45.
Nochioka K et al (2017) Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 18(10):1128–1137PubMed
46.
Plehn JF, Southworth J, Cornwell GG 3rd (1992) Brief report: atrial systolic failure in primary amyloidosis. N Engl J Med 327(22):1570–1573PubMedCrossRef
47.
Reddy VY et al (2017) 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 70(24):2964–2975PubMedCrossRef
48.
Dubrey SW et al (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91(2):141–157PubMedCrossRef
49.
Epstein AE et al (2013) 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 127(3):e283-352PubMedCrossRef
50.
Kristen AV et al (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5(2):235–240PubMedCrossRef
51.
Dhoble A et al (2009) Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol 32(8):E63–E65PubMedPubMedCentralCrossRef
52.
Lin G, Dispenzieri A, Brady PA (2010) Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. Eur Heart J 31(12):1538–1538PubMedCrossRef
53.
Lin G et al (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 24(7):793–798PubMedCrossRef
54.
Varr BC et al (2014) Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm 11(1):158–162PubMedCrossRef
55.
Siegismund CS et al (2018) Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail 20(4):751–757PubMedCrossRef
56.
57.
Maurer MS et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007–1016PubMedCrossRef
58.
Kim EJ et al (2020) Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace 22(8):1216–1223PubMedCrossRef
59.
Chen J et al (2013) Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol 61(21):2161–2168PubMedPubMedCentralCrossRef
60.
Reisinger J et al (1997) Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 30(4):1046–1051PubMedCrossRef
61.
Donnellan E et al (2019) Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol 30(11):2427–2432PubMedCrossRef
62.
Anker SD et al (1997) Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349(9058):1050–1053PubMedCrossRef
63.
Fülster S et al (2013) Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 34(7):512–519PubMedCrossRef
64.
Escher F et al (2020) When and how do patients with cardiac amyloidosis die? Clin Res Cardiol 109(1):78–88PubMedCrossRef
65.
Rozentryt P et al (2010) The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle 1(1):35–42PubMedPubMedCentralCrossRef
66.
67.
White JV et al (2012) Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). J Acad Nutr Diet 112(5):730–738PubMedCrossRef
68.
69.
Sidebottom AC et al (2015) Inpatient palliative care for patients with acute heart failure: outcomes from a randomized trial. J Palliat Med 18(2):134–142PubMedCrossRef
70.
Pathak A et al (2005) Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol 61(5–6):471–474PubMedCrossRef
71.
Hauser RA et al (2015) Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord 30(5):646–654PubMedCrossRef
72.
Sobol SM, Rakita L (1982) Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation 65(4):819–824PubMedCrossRef
73.
74.
Trip MD, Wiersinga W, Plomp TA (1991) Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 91(5):507–511PubMedCrossRef
75.
Lewis JH et al (1989) Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 9(5):679–685PubMedCrossRef
Metadaten
Titel
Clinical management of amyloid cardiomyopathy
verfasst von
Morris M. Kim
Clinton M. Kolseth
Dayna Carlson
Ahmad Masri
Publikationsdatum
01.09.2021
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 5/2022
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-021-10159-w

Weitere Artikel der Ausgabe 5/2022

Heart Failure Reviews 5/2022 Zur Ausgabe

ReviewPaper

Targeted treatments of AL and ATTR amyloidosis

ReviewPaper

Resistance training in heart failure patients: a systematic review and meta-analysis

ReviewPaper

State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond

ReviewPaper

Epidemiology and clinical manifestations of cardiac amyloidosis

ReviewPaper

Echocardiographic assessment of cardiac amyloidosis

ReviewPaper

Advanced airway management and respiratory care in decompensated pulmonary hypertension

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise